Raphael Vinod P, Shanmughan Shaju K
Department of Chemistry, Government Engineering College, Thrissur, Kerala, 680009, India.
Adv Pharmacol Pharm Sci. 2020 Sep 21;2020:8818008. doi: 10.1155/2020/8818008. eCollection 2020.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus behind the fast-spreading coronavirus disease 2019 (COVID-19). Pharmaceutical researchers are currently researching medications or preventive vaccines that may be used to treat and combat the spread of COVID-19. Health practitioners all over the world are treating patients with currently available antiviral drugs, primarily the protease inhibitors used for HIV treatment. The present study mainly aims to evaluate the potencies of eight anti-HIV drugs to inhibit coronavirus protease using methods. Derivation of pharmacophore, identification of hit molecules, and checking their virtual inhibition efficacies on the COVID-19 protease were also carried out in the present investigation. Classification of eight drug molecules (atazanavir, darunavir, fosamprenavir (amprenavir-metabolised product), saquinavir, lopinavir, ritonavir, nelfinavir, and indinavir) based on their molecular structures was completed and reported. The X-ray crystallographic structure of the main protease of coronavirus (SARS-CoV-2 protease) was obtained from the Protein Data Bank and prepared for computational studies using Edu PyMOL software. Docking studies were performed with AutoDock Vina software, and the results were evaluated with Discovery Studio software. The binding scores of the drugs on protease followed the order saquinavir > nelfinavir > lopinavir = indinavir > darunavir > amprenavir > ritonavir > atazanavir. Web servers such as PharmaGist and ZINCPharmer were employed to derive the 3D pharmacophore and to identify potential hit compounds, respectively. The identified hit molecules were docked with the SARS-CoV-2 protease and analysed. A detailed account of the type of interaction between the protease and the molecules is discussed. The majority of hit compounds displayed appreciable binding affinities on coronavirus protease. Three hit compounds possess structures similar to that of natural products, viz., flavonoids, and nucleoside. These molecules were hydrophilic and slightly deviated from Lipinski parameters. All other derived molecules obeyed the Lipinski rule. , and toxicological studies of these compounds have to be performed before checking the actual druggability of these compounds.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)是快速传播的2019冠状病毒病(COVID-19)背后的新型冠状病毒。药物研究人员目前正在研究可用于治疗和对抗COVID-19传播的药物或预防性疫苗。世界各地的医疗从业者正在用现有的抗病毒药物治疗患者,主要是用于治疗HIV的蛋白酶抑制剂。本研究主要旨在使用相关方法评估八种抗HIV药物抑制冠状病毒蛋白酶的效力。本研究还进行了药效团的推导、命中分子的鉴定以及检查它们对COVID-19蛋白酶的虚拟抑制效果。基于八种药物分子(阿扎那韦、达芦那韦、福沙普那韦(安普那韦代谢产物)、沙奎那韦、洛匹那韦、利托那韦、奈非那韦和茚地那韦)的分子结构进行了分类并报告。冠状病毒主要蛋白酶(SARS-CoV-2蛋白酶)的X射线晶体学结构从蛋白质数据库中获取,并使用Edu PyMOL软件进行计算研究准备。使用AutoDock Vina软件进行对接研究,并使用Discovery Studio软件评估结果。药物在蛋白酶上的结合分数顺序为沙奎那韦>奈非那韦>洛匹那韦=茚地那韦>达芦那韦>安普那韦>利托那韦>阿扎那韦。分别使用PharmaGist和ZINCPharmer等网络服务器推导3D药效团和识别潜在的命中化合物。将鉴定出的命中分子与SARS-CoV-2蛋白酶进行对接并分析。讨论了蛋白酶与分子之间相互作用类型的详细情况。大多数命中化合物在冠状病毒蛋白酶上显示出可观的结合亲和力。三种命中化合物具有与天然产物类似的结构,即黄酮类化合物和核苷。这些分子具有亲水性,略微偏离了Lipinski参数。所有其他推导分子均符合Lipinski规则。在检查这些化合物的实际成药性之前,必须对这些化合物进行进一步的研究和毒理学研究。